Edibles are pharmacologically different from smoking — delayed onset, liver metabolism to the more potent 11-OH-THC, and unpredictable absorption create unique safety risks that require specific regulation.
Anyone who uses edibles, anyone new to cannabis, parents concerned about child safety, clinicians advising patients, and regulators developing cannabis policy.
83% of edibles tested had THC content that differed from the label by more than 10%
The Backstory
On the evening of March 11, 2014, a 19-year-old college student named Levy Thamba Pongi bought a cannabis cookie from a licensed dispensary in Denver. The sales clerk told him to divide the cookie into sixths — each piece containing roughly 10 milligrams of THC, a single serving. He ate one piece. Thirty minutes later, he felt nothing. So he ate the rest.
Within two hours, Levy was exhibiting erratic speech and hostile behavior. Three and a half hours after his first bite, he jumped from a fourth-floor hotel balcony. The coroner ruled marijuana intoxication a chief contributing factor. He was Colorado's first cannabis-only death since recreational legalization — and the case that forced everyone to reckon with a fact that pharmacologists had known for decades: edibles are not just a different delivery method. They are a fundamentally different drug experience.
The Problem Nobody Anticipated
Colorado legalized recreational cannabis sales on January 1, 2014. Within months, the emergency departments told the story the legislature hadn't predicted.
33x
disproportionate — edibles accounted for only 0.32% of total cannabis sales in Colorado from 2014-2016, but were responsible for 10.7% of all cannabis-related emergency department visits at UCHealth University of Colorado Hospital.
Put another way: for every dollar spent on edibles relative to other cannabis products, the ER saw 33 times more patients. This is not a marginal difference — it is a structural failure of the product category as it existed in 2014.
Monte et al. (2019), Annals of Internal Medicine
The reasons were not mysterious. They were pharmacological.
Why Edibles Hit Different (and Harder)
The core problem is the liver. When you smoke cannabis, THC enters your lungs, passes into your bloodstream, and reaches your brain in seconds. When you eat cannabis, THC takes a detour through the portal vein to the liver, where the enzyme CYP2C9 converts it into 11-hydroxy-THC — a metabolite that crosses the blood-brain barrier more efficiently and binds CB1 receptors with dramatically higher affinity.
Process
The Edible Pharmacokinetic Problem
Delayed Absorption
THC must pass through the stomach and small intestine before entering the bloodstream. This takes 30 to 90 minutes — sometimes up to 2 hours. During this window, the user feels nothing and is tempted to redose.
Low Bioavailability
Only 6-10% of ingested THC reaches systemic circulation, compared to roughly 30% from smoking. But the THC that does make it through has been partially converted to 11-OH-THC by the liver — a more potent molecule.
Metabolic Conversion
The liver converts a substantial fraction of oral THC to 11-OH-THC via first-pass metabolism. Colorado's own independent analysis estimated that 1mg of THC in an edible produces behavioral effects equivalent to 5.71mg of smoked THC — a nearly 6x potency multiplier.
Prolonged Duration
Effects from edibles peak at 2-4 hours and can last 8-12 hours. At high doses or in sensitive individuals, residual effects can persist for 24 hours or more. There is no way to 'come down faster' once THC and 11-OH-THC are in systemic circulation.
Barrus et al. (2016); Lemberger et al. (1972); Colorado independent analysis
The Numbers That Shaped Regulation
The Barrus review compiled the evidence that would reshape cannabis regulation nationwide:
Key Takeaways
The Labeling Problem
Myth vs. Reality
If a dispensary edible says 10mg THC on the label, that's what you're getting
When Barrus et al. compiled labeling accuracy data, they found that 83% of tested edibles deviated from labeled THC content by more than 10%. Some products contained nearly double the stated amount; others had almost none. This was not a minor calibration issue — it was a fundamental quality control failure across the industry. A subsequent study by Vandrey et al. found similar results, and Bonn-Miller et al. (2017) documented the same pattern in CBD products.
The Evidence
Barrus et al. (2016); Vandrey et al. (2015); Bonn-Miller et al. (2017)
The labeling problem compounded the pharmacokinetic problem. A consumer who carefully ate a single 10mg serving might actually be consuming 5mg or 20mg, with no way to know. Combined with the 30-90 minute onset delay, the potential for accidental overconsumption was structural, not behavioral. The system was designed to fail.
The Child Safety Crisis
The pediatric exposure data was among the most politically consequential findings. Before legalization, Children's Hospital Colorado saw essentially no cases of accidental cannabis ingestion. After recreational sales began, cases appeared immediately — and they were not trivial.
- Product appeal high
Gummies, chocolates, cookies, and lollipops are indistinguishable from regular candy to a child. Even after packaging reforms, the products themselves remain attractive to children.
- Dose relative to body weight critical
A 10mg serving designed for an adult can produce severe effects in a 20kg child — the equivalent of 3-5x the intended adult dose by body weight.
- Delayed recognition high
Parents may not realize a child has consumed an edible until symptoms appear 1-2 hours later. By then, the dose is fully absorbed and cannot be reversed.
- Symptom severity high
Pediatric presentations include lethargy, ataxia, respiratory depression, and in severe cases, coma. Children lack the cognitive framework to understand what is happening, amplifying distress.
Barrus et al. (2016); Wang et al. (2016); Children's Hospital Colorado data
What Changed Because of This Review
The Barrus review was not published in a vacuum. It was part of RTI International's policy research program, funded by NIDA, and it landed at exactly the moment regulators needed evidence-based guidance. The policy cascade was rapid:
Research Timeline
From Evidence to Regulation
Historical research record
What People Still Get Wrong
Myth vs. Reality
10mg is a safe starting dose for everyone
The 10mg standard is a regulatory unit, not a clinical recommendation. For edible-naive individuals, even 10mg can produce significant anxiety, disorientation, and hours-long impairment. Clinical practitioners like Dustin Sulak recommend starting at 2.5mg — sometimes even 1mg — and waiting at least 2 hours before considering more. The 10mg 'dose' was designed to be the maximum for a single serving, not the minimum effective dose.
The Evidence
Barrus et al. (2016); Sulak (2019) microdosing protocol
The edible dosing conversation remains one of the most important in cannabis safety. The pharmacology hasn't changed since Lemberger described 11-OH-THC in 1972. The regulatory framework has improved enormously since Barrus compiled the evidence in 2016. But the fundamental challenge — a drug with delayed onset, unpredictable absorption, and metabolic potentiation in a format that looks like candy — remains.
For practical dosing guidance, our cannabis dosing guide walks through the specifics. For edible-specific timing and sleep applications, see our edibles for sleep guide. And for the pharmacological explanation of why edibles feel qualitatively different, the Lemberger 1972 study is the place to start.
How long should I wait before taking more of an edible?
At minimum 2 hours, ideally 3-4 hours for a first-time user. The Barrus review documents onset times of 30-90 minutes, but individual variation is enormous. Factors including stomach contents, body fat percentage, liver enzyme genetics, and product formulation all affect timing. The single most common edible mistake — documented repeatedly in Colorado ER data — is redosing too early because the first dose "didn't work yet."
Why are edibles so much stronger than smoking the same amount of THC?
Two reasons. First, your liver converts oral THC into 11-OH-THC, a metabolite that binds CB1 receptors more potently and crosses the blood-brain barrier more efficiently. Colorado's analysis estimated 1mg oral THC produces effects equivalent to 5.71mg smoked THC. Second, the extended duration (8-12 hours vs. 1-3 hours for smoking) means the total psychoactive exposure per milligram is much higher.
What should I do if I take too much?
The single most important thing: you will be okay. No one has ever died from THC toxicity alone. The acute effects — anxiety, paranoia, rapid heartbeat, disorientation — are uncomfortable but temporary. Move to a calm, comfortable environment. Hydrate. If you have CBD available, some evidence suggests it may blunt THC's acute effects. The effects will wear off, though with edibles this can take several hours. If symptoms are severe (chest pain, inability to breathe, psychotic symptoms), seek medical attention — ER staff see this regularly and will not judge you.
Are dispensary edibles accurately dosed now?
Significantly better than in 2014, but still imperfect. The Barrus review found 83% of tested products differed from labeled amounts by more than 10%. Regulatory reforms have improved this: most states now require third-party lab testing and mandate accuracy within +/- 10-15% of labeled THC. Licensed dispensary products from regulated markets are far more reliable than homemade edibles, where THC distribution is essentially random.
Can children accidentally get into edibles?
Yes, and this remains a serious concern. Pediatric exposures in Colorado went from zero before legalization to 14 cases at Children's Hospital in 2014 alone. All legal states now mandate child-resistant packaging, but the products themselves — gummies, chocolates, cookies — are inherently appealing to children. The Barrus review recommended (and regulations now require) that edibles cannot resemble commercially available candy or be marketed in forms appealing to children. Store edibles securely, as you would medications.
Tasty THC: Promises and Challenges of Cannabis Edibles
Barrus DG, Capogrossi KL, Cates SC, Gourdet CK, Peiper NC, Novak SP, Lefever TW, Wiley JL (2016) · Methods Report, RTI Press
Related Research
Key studies in this area
Why Edibles Hit Different: The 11-OH-THC Metabolite
Lemberger et al. (1972)
Microdosing Cannabis: The Sensitization Protocol
Sulak (2019)
THC vs CBD Labeling Accuracy
Bonn-Miller et al. (2017)
Unintentional Pediatric Exposures to Marijuana in Colorado, 2009-2015
Wang et al. (2016)
Edible Marijuana Product Exposures Reported to US Poison Control Centers
Cao et al. (2016)
What the researchers found
Cannabis edibles present unique safety challenges due to delayed onset (30-90 min), unpredictable bioavailability (6-10%), and the potent liver metabolite 11-OH-THC, leading to disproportionate adverse events and ER visits relative to market share
Why it matters
This review directly informed the 10mg standard serving size now adopted by most legal states and became the definitive reference for edible safety policy. It documented that edible-related ER visits doubled in Colorado after legalization and that 83% of tested products had inaccurate labels.
The numbers in context
10mg standard serving size; 100mg max per recreational product; 30-90 minute onset delay; 6-10% oral THC bioavailability; 1mg oral THC ≈ 5.71mg smoked THC behavioral equivalence; 83% of tested edibles had inaccurate labels; ER visits doubled from 85 to 168 per 10,000 in Colorado 2013-2014; poison control calls increased 30.3% per year in decriminalized states 2005-2011
How the study worked
Narrative review synthesizing pharmacokinetic literature, epidemiological data from Colorado and Washington, poison control center data, regulatory frameworks from four legalized states (CO, WA, OR, AK), and food labeling research
Who was studied
Review covers general adult cannabis users, pediatric populations (accidental exposure), tourists/naive users, and regulatory frameworks
What this study cannot tell us
Review article, not original research; data primarily from Colorado and Washington as earliest legalizers; pre-dates the larger Monte 2019 ER data; regulatory landscape rapidly evolving; limited long-term outcome data
How to read the evidence
This is a narrative review, not a systematic review or original research. Its strength lies in comprehensively synthesizing pharmacokinetic data, epidemiological evidence, and regulatory frameworks into a single accessible policy document. The individual data points it draws from (Colorado ER data, labeling studies, pharmacokinetic research) range from moderate to strong evidence.
When this study was published
Published November 2016, when only four states had recreational cannabis. The regulatory landscape has expanded dramatically, but the pharmacokinetic fundamentals and the 10mg standard it helped establish remain current. Newer data (Monte 2019) has strengthened its core findings.
The bigger picture
Barrus et al. turned anecdotal evidence of edible problems into a systematic policy document. Before this review, edible regulation was ad hoc. After it, the 10mg standard serving became the consensus regulatory approach. The study also foreshadowed Monte's 2019 finding that edibles account for only 0.32% of sales but 10.7% of cannabis-related ER visits — a 33-fold disproportion.
Common questions
Read the original research
Tasty THC: Promises and Challenges of Cannabis Edibles
Methods Rep RTI Press
RTI International research report series — peer-reviewed policy publications from one of the largest independent nonprofit research institutes in the US
Citation
Barrus DG, Capogrossi KL, Cates SC, Gourdet CK, Peiper NC, Novak SP, Lefever TW, Wiley JL. (2016). Tasty THC: Promises and Challenges of Cannabis Edibles. Methods Rep RTI Press. https://doi.org/10.3768/rtipress.2016.op.0035.1611